SMAD-signaling inhibition: potential for developing newer treatments for corneal fibrosis [abstract]
Metadata[+] Show full item record
Transforming growth factor β (TGFb) is known to cause fibrosis in the cornea following injury and/or infection. Effective reduction in corneal fibrosis has been reported by inhibiting TGFb activity. However, associated molecular mechanism is still unknown. The aim of study was to test the hypothesis that the alteration in SMAD signaling is a novel approach for treating corneal fibrosis using an established in vitro model.